| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-732 | |
| Phytochemical name or plant extracts | Nigella sativa extract | |
| PMID | 25520084 | |
| Literature evidence | NS could potentially represent an alternative source of medicine for breast cancer therapy. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Methanolic extract | |
| Source of phytochemicals or plant Extracts | Nigella sativa | |
| Geographical availability | Bulgaria, Cyprus, Iran, Iraq, North Caucasus, Romania, Transcaucasus, Turkey, Turkmenistan | |
| Plant parts | Seeds | |
| Other cancers | Breast cancer | |
| Target gene or protein | Caspase 3, Caspase 8, Caspase 9, p53, Cyclin D1, p21 , PAK1, Bcl-2, VEGF | |
| Gene or Protein evidence | Similarly, the expression of the Caspase-3, -8, -9 and p53 genes increased significantly according to the dose and time. The pathway analysis was performed using the PANTHER tool by using five randomly selected N. sativa affected genes (Cyclin D1, P53, p21 protein (Cdc42/Rac) activated kinase 1 (PAK1), B-cell lymphoma 2 (Bcl-2) and vascular endothelial growth factor (VEGF)) in order to elucidate further potentially affected signaling pathways. | |
| Target pathways | p53 and caspase pathways | |
| IC50 | 62.8 μL/mL against MCF-7 | |
| Potency | NS induced apoptosis in MCF-7 cells through both the p53 and caspase pathways. | |
| Cell line/ mice model | MCF-7 | |
| Additional information | NS could potentially represent an alternative source of medicine for breast cancer therapy. | |
| PubChem ID | NA | |
| Additional PMIDs | 26964971 31141941 32351178 34206999 12724920 23900121 24328702 23242945 25520084 31679281 31780017 32020890 22895066 28250648 28606050 24941454 20087986 25771001 27141285 30564115 34490824 33845751 34816327 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:711687-1 | |
| Safety | NA |